세계 림프부종 치료 시장 – 2024-2031년

Global Lymphedema Treatment Market - 2024-2031

상품코드PH8501
발행기관DataM Intelligence
발행일2024.07.10
페이지 수182 Pages
포맷PDF + EXCEL
커버리지Global

₩6,525,000 – ₩11,775,000

보고서 요약(국문)

개요
전 세계 림프부종 치료 시장은 2023년 11억 달러 규모에 달했으며, 2024년부터 2031년까지 연평균 9.5%의 성장률을 보이며 2031년에는 23억 달러에 이를 것으로 예상됩니다.
림프부종은 단백질이 풍부한 체액이 체내 림프계를 통해 배출되지 못하고 축적되어 조직이 붓는 질환입니다. 주로 팔이나 다리에 발생하지만, 흉벽, 복부, 목, 생식기에도 나타날 수 있습니다.
림프절은 림프계의 중요한 구성 요소입니다. 림프부종은 암 치료 과정에서 림프절을 제거하거나 손상시키는 경우 발생할 수 있으며, 림프액 배출을 방해하는 모든 문제가 림프부종을 유발할 수 있습니다.
림프부종 치료는 일반적으로 물리 치료와 함께 림프부종 부위의 체액 이동을 돕는 압박복이나 붕대를 사용하는 방법을 병행합니다.

시장 동향: 성장 동력
림프부종 치료를 위한 기술 발전 증가
전 세계 림프부종 시장의 수요는 여러 요인에 의해 주도되고 있습니다. 그중 핵심적인 요인은 의료 시스템의 기술 발전입니다. 림프부종은 일반적으로 림프 배액 부족으로 인해 발생하는 만성 질환입니다.
주요 기업들의 혁신적인 기술 발전은 시장 성장을 견인하는 데 도움이 됩니다. 이러한 효과적인 기술 발전은 연구 결과를 새로운 치료법으로 전환하고 수백만 명의 림프부종 환자들에게 더 나은 치료를 제공하는 데 기여합니다. 예를 들어, 2022년 10월 ImpediMed Limited는 유방암 환자의 림프부종 영향을 줄이기 위해 주요 암 센터에서 자사의 SOZO 디지털 헬스 플랫폼 사용을 확대한다고 발표했습니다.
또한, 주요 기업들이 림프부종 치료에 대한 첨단 연구 개발을 도입하고 새로운 치료법과 약물을 출시하는 것도 시장 성장을 촉진할 것입니다. 예를 들어, 2023년 4월 AIROS Medical, Inc.는 림프부종 치료용 새로운 연동식 공기압 압박 장치인 체간 압박복에 대해 미국 식품의약국(FDA)의 시판 승인을 받았다고 발표했습니다.
또한, 2022년 4월 Koya Medical은 하지 림프부종 및 정맥 질환 치료를 위한 Dayspring 능동 압박 시스템의 미국 시장 출시를 발표했습니다. Dayspring은 미국 식품의약국(FDA)의 승인을 받은 최초의 비공기압식 능동 동적 압박 치료법입니다. 이처럼 위의 요인들은 시장 성장을 촉진하는 데 도움이 됩니다.
제한 요인
치료 절차의 높은 비용, 줄기세포 치료와 관련된 부작용, 제한된 치료 옵션, 그리고 개인의 인식 및 진단 부족과 같은 요인들이 시장 성장을 저해할 것으로 예상됩니다.
세분화 분석
글로벌 림프부종 치료 시장은 유형, 치료, 최종 사용자 및 지역별로 세분화됩니다.

림프부종 치료 시장에서 울혈 완화 요법 부문은 전 세계 시장 점유율의 약 43.2%를 차지했습니다.
울혈 완화 요법 부문은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 전 세계적으로 치료 요법에 대한 임상 시험이 증가함에 따라 림프부종 치료에 대한 수요가 증가하고 있습니다. clinicalTrials.gov에 따르면, 2022년 7월 굴하네 의과대학(Gulhane School of Medicine)은 대사 증후군이 림프부종 환자의 복합 울혈 완화 물리 치료 결과에 미치는 영향에 대한 임상 시험을 진행했습니다. 이 시험의 목적은 대사 증후군이 있는 환자와 없는 환자에서 복합 울혈 완화 물리 치료(KBF)의 효과를 비교하는 것입니다.
또한, 업계 주요 기업들의 림프부종 치료 연구가 이 부문의 성장을 견인할 것입니다. 예를 들어, 2023년 7월 카이로 대학교(Cairo University)는 상지 림프부종(CDT) 후 수근관 증후군에 대한 완전 울혈 완화 요법의 효과에 대한 임상 시험을 진행했습니다. 환자는 간헐적 공기압박, 운동, 붕대 감기, 수동 림프 배액 등의 형태로 완전한 울혈 완화 치료를 받습니다. 따라서 위의 요인들이 시장 성장을 가속화하는 데 도움이 됩니다.
또한, 2022년 5월, PureTech Health는 미국 흉부학회 2022 국제 학술대회에서 PureTech의 LYT-100(듀피르페니돈)에 대한 추가 데이터를 발표했습니다. LYT-100은 유사한 노출 수준에서 피르페니돈에 비해 부작용 발생률이 낮았으며, 내약성이 향상된 것으로 나타났습니다. 이는 폐 질환 및 림프부종과 같은 림프 흐름 장애를 포함하여 염증 및 섬유화와 관련된 질환의 잠재적 치료제입니다.

지리적 분석
북미는 전 세계 림프부종 치료 시장의 약 41.2%를 차지했습니다.
미국과 캐나다에서 림프부종 유병률과 유방암 발병률이 증가함에 따라 북미 지역은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다.
림프부종 교육 및 연구 네트워크(Lymphatic Education & Research Network)에 따르면 2024년 전 세계적으로 최대 2억 5천만 명이 림프부종(LE)을 앓고 있으며, 미국에서는 약 1천만 명이 림프부종을 앓고 있는 것으로 추산됩니다. 또한 유방암 생존자의 최대 30%가 심각한 림프부종을 경험합니다.
더욱이, 이 지역에서는 주요 기업의 파트너십 및 협력, 잘 발달된 의료 시스템, 그리고 신제품 출시가 시장 성장을 촉진할 것입니다. 예를 들어, 2023년 6월 폴 하트만(PAUL HARTMANN AG)은 림프부종 치료를 위한 압박 요법에 사용되는 혁신적인 압박 붕대 및 라이너 제품군에 대해 시그바리스(Sigvaris)와 파트너십을 발표했습니다.

또한, 2022년 10월 임페디메드는 암 환자 치료에 전념하는 글로벌 조직인 제네시스 케어와 함께 림프부종 예방 프로그램을 미국에서 시작한다고 발표했습니다.
마찬가지로, 2024년 3월 NHLBI는 NIH 산하 최초의 림프계 질환 국가위원회를 출범시키는 데 도움을 주었습니다. 이 림프계 위원회의 설립은 매우 중요하지만 상대적으로 소홀히 여겨져 온 연구 분야에서 고무적이고 혁신적인 진전입니다.

시장 세분화
유형별
• 원발성 림프부종
• 이차성 림프부종
치료법별
• 줄기세포 치료
• 울혈 완화 요법
• 수술
• 약물 치료
• 레이저 치료
• 기타
최종 사용자별
• 병원
• 클리닉
• 외래 수술 센터
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 한국
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
림프부종 시장의 주요 글로벌 업체로는 Kite Pharma, Johnson & Johnson, Sanofi S.A, LGM Pharma, Hubei Xunda Pharma, Sigma Aldrich, Midas Pharma, Oishi Koseido 등이 있습니다. Co. Ltd, Glentham Life Sciences, Taro Pharmaceuticals 등이 있습니다.
주요 개발 사항
 2023년 8월, Calamos Advisors LLC는 Tactile Systems Technology, Inc.의 주식 60,861주를 인수하여 상당한 투자를 진행했습니다. 이 인수 금액은 약 999,000달러이며, Tactile Systems Technology의 지분 0.26%를 확보한 것입니다. Tactile Systems Technology는 림프부종, 정맥 질환, 폐 분비물 저류 등의 질환 치료를 위한 혁신적인 기기 개발에 전념하는 의료 기술 회사입니다.

 2022년 6월, Hyperice는 일상적인 건강 증진, 빠른 회복 및 훈련 효과 향상을 위해 동적 공기 압축 기술을 사용하는 대표적인 Normatec 시리즈의 차세대 제품인 Normatec 3를 출시했습니다. Normatec은 림프절 제거 또는 손상으로 인해 림프부종을 겪는 유방암 치료 환자를 돕기 위해 개발되었습니다.

 2022년 5월, 호스피스 자선 단체는 AECC 대학교와 협력하여 새로운 림프부종 서비스를 제공합니다. 이 계획은 루이스-매닝 호스피스 케어(Lewis-Manning Hospice Care)의 이동식 림프부종 클리닉 시범 운영 성공에 힘입어, 환자들에게 더 가까운 곳에서 서비스를 제공하고 접근성을 높이는 것을 목표로 합니다.
보고서 ​​구매 이유:

• 유형, 치료법, 최종 사용자 및 지역별 글로벌 림프부종 치료 시장 세분화를 시각화하고 주요 상업 자산 및 업체들을 파악할 수 있습니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴할 수 있습니다.

• 모든 세그먼트를 포함한 글로벌 림프부종 치료 시장 수준의 다양한 데이터가 담긴 엑셀 파일 제공.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서 제공.

• 주요 업체들의 핵심 제품 정보를 담은 엑셀 파일 제공.

글로벌 림프부종 치료 시장 보고서는 약 69개의 표, 70개의 그림, 182페이지 분량으로 구성됩니다.

2023년 목표 고객층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
The global lymphedema treatment market reached US$ 1.1 billion in 2023 and is expected to reach US$ 2.3 billion by 2031 growing with a CAGR of 9.5% during the forecast period 2024-2031.
Lymphedema refers to tissue swelling caused by an accumulation of protein-rich fluid that's usually drained through the body's lymphatic system. It most commonly affects the arms or legs, but can also occur in the chest wall, abdomen, neck, and genitals.
Lymph nodes are an important part of the lymphatic system. Lymphedema can be caused by cancer treatments that remove or damage the lymph nodes. Any type of problem that blocks the drainage of lymph fluid can cause lymphedema.
Lymphedema treatment typically includes a combination of physical therapy and garments or bandaging that moves fluid from areas affected by lymphedema.
Market Dynamics: Drivers
Increasing Technological Advancements for Lymphedema Treatment
The demand for the global lymphedema market is driven by multiple factors. One of the key factors is the technological advancements in the healthcare system. Lymphedema is a chronic condition that is usually caused by insufficient lymphatic drainage.
The innovative technological advancements by key companies help to drive market growth. These effective advancements help to transform research discoveries into new treatments and improve care for millions of people with lymphedema. For instance, in October 2022, ImpediMed Limited announced the expansion of the use of its SOZO Digital Health Platform at leading cancer centers dedicated to reducing the impact of lymphedema on breast cancer patients.
Moreover, key players introducing advanced research & developments in treating lymphedema and launching new therapies & drugs would drive this market growth. For instance, in April 2023, AIROS Medical, Inc. announced that it received U.S. Food and Drug Administration (FDA) clearance to market a new peristaltic pneumatic compression device, truncal garments for lymphedema treatment.
Also, in April 2022, Koya Medical announced the U.S. commercial availability of its Dayspring active compression system for the treatment of lymphedema and venous diseases in the lower extremities. Dayspring is the first non-pneumatic active dynamic compression treatment cleared by the U.S. Food and Drug Administration (FDA). Thus, the above factors help to boost the market growth.
Restraints
Factors such as the high cost of the treatment procedure, side effects associated with stem cell therapy treatment, limited treatment options, and lack of awareness & diagnosis among individuals, are expected to hamper the market.
Segment Analysis
The global lymphedema treatment market is segmented based on type, treatment, end users, and region.
The decongestive therapy segment accounted for approximately 43.2% of the global lymphedema treatment market share
The decongestive therapy segment is expected to hold the largest market share over the forecast period. The rising clinical trials of treatment therapy globally have contributed to the growing demand for lymphedema treatment. According to clinicalTrials.gov, in July 2022, Gulhane School of Medicine conducted a clinical trial on the Effect of Metabolic Syndrome on Complex Decongestive Physiotherapy Outcomes in Lymphedema Patients. The aim is to compare the effectiveness of complex decongestive physiotherapy (KBF) in patients with and without metabolic syndrome.
Moreover, key players in the industry research studies in the treatment of lymphedema would drive this segment growth. For instance, in July 2023, Cairo University conducted a clinical trial on the Effect Of Complete Decongestive Therapy on Carpal Tunnel Syndrome Post Upper Limb Lymphedema (CDT). The patients receives complete decongestive therapy in the form of intermittent pneumatic compression, exercising, bandaging, and manual lymphatic drainage. Thus, the above factors help to accelerate the market growth.
Also, in May 2022, PureTech Health announced the presentation of additional data for PureTech’s LYT-100 (deupirfenidone) at the American Thoracic Society 2022 International Conference. LYT-100 demonstrated a lower incidence of adverse events (AEs) compared to pirfenidone at comparable exposure levels and observed improved tolerability of LYT-100. It is the potential treatment of conditions involving inflammation and fibrosis, including lung disease and disorders of lymphatic flow, such as lymphedema.
Geographical Analysis
North America accounted for approximately 41.2% of the global lymphedema treatment market share
North America region is expected to hold the largest market share over the forecast period owing to the rising prevalence of lymphedema, and rising breast cancer, in the U.S., and Canada driving the market growth.
As per Lymphatic Education & Research Network in 2024, up to 250 million people worldwide have lymphedema (LE) with an estimated 10 million living with lymphedema (LE) in the United States, up to 30% of breast cancer survivors acquire debilitating LE.
Moreover, in this region, a major key player's partnerships & collaborations, well-advanced healthcare system, and new product launches would propel this market growth. For instance, in June 2023, PAUL HARTMANN AG announced its partnership with Sigvaris for the innovative compression wraps and liners range that are used as compression therapy for the treatment of lymphedema.
Also, in October 2022, ImpediMed announced the U.S. launch of a lymphedema prevention program with Genesis Care, a global organization dedicated to the care of cancer patients.
Similarly, in March 2024, NHLBI helps launch the first NIH National Commission on Lymphatic Diseases. The creation of this lymphatics commission is a gratifying and revolutionary step in this very important and relatively neglected field of research.
Market Segmentation
By Type
• Primary Lymphedema
• Secondary Lymphedema
By Treatment
• Stem Cell Therapy
• Decongestive therapy
• Surgery
• Drug Therapy
• Laser Therapy
• Others
By End Users
• Hospital
• Clinics
• Ambulatory Surgical Centers
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the lymphedema market include Kite Pharma, Johnson, and Johnson, Sanofi S.A, LGM Pharma, Hubei Xunda Pharma, Sigma Aldrich, Midas Pharma, Oishi Koseido Co. Ltd, Glentham Life Sciences, Taro Pharmaceuticals among others.
Key Developments
 In August 2023, Calamos Advisors LLC made a significant investment in Tactile Systems Technology, Inc. by acquiring 60,861 shares of the company’s stock. The purchase amounted to approximately $999,000 and represented 0.26% ownership of Tactile Systems Technology. Tactile Systems Technology is a medical technology company dedicated to developing innovative devices for the treatment of conditions such as lymphedema, venous disorders, and pulmonary secretions retention.
 In June 2022, Hyperice, launched Normatec 3, the next evolution of the iconic Normatec series which uses dynamic air compression to advance everyday wellness and helps aid in faster recovery, and improved training. Normatec was developed to help people undergoing breast cancer treatment who often suffer from lymphedema caused by removal or damage to their lymph nodes.
 In May 2022, Hospice charity partners with AECC University College to provide new lymphoedema service. The initiative follows the success of Lewis-Manning Hospice Care’s pilot mobile lymphoedema clinics by bringing its services closer to people’s homes and making the service accessible and easy.
Why Purchase the Report?
• To visualize the global lymphedema treatment market segmentation based on type, treatment, end users and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global lymphedema treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global lymphedema treatment market report would provide approximately 69 tables, 70 figures, and 182 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Treatment
3.3. Snippet by End Users
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Technological Advancements for Lymphedema Treatment
4.1.1.2. Increasing Prevalence of Cancer and Government Initiatives & Funding
4.1.2. Restraints
4.1.2.1. High Cost of the Treatment Procedure
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. By Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index, By Type
6.2. Primary Lymphedema
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Secondary Lymphedema
7. By Treatment
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
7.1.2. Market Attractiveness Index, By Treatment
7.2. Decongestive therapy
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Surgery
7.4. Drug Therapy
7.5. Laser Therapy
7.6. Others
8. By End Users
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
8.1.2. Market Attractiveness Index, By End Users
8.2. Hospital Pharmacy
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Retail Pharmacy
8.4. Online Pharmacy
8.5. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
9.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Product Benchmarking
10.3. Company Share Analysis
10.4. Key Developments and Strategies
11. Company Profiles
11.1. Kite Pharma*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Johnson and Johnson
11.3. Sanofi S.A
11.4. LGM Pharma
11.5. Hubei Xunda Pharma
11.6. Sigma Aldrich
11.7. Midas Pharma
11.8. Oishi Koseido Co. ltd
11.9. Glentham Life Sciences
11.10. Taro Pharmaceuticals
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us

언급된 주요 기업들

Kite Pharma, 4. Key Developments, Johnson and Johnson, Sanofi S.A, LGM Pharma, Hubei Xunda Pharma, Sigma Aldrich, Midas Pharma, Oishi Koseido Co. ltd, Glentham Life Sciences, Taro Pharmaceuticals

표 목록 (Tables)

List of Tables

Table 1 Global Lymphedema Treatment Market Value, By Type, 2023, 2027 & 2031 (US$ Billion)

Table 2 Global Lymphedema Treatment Market Value, By Treatment, 2023, 2027 & 2031 (US$ Billion)

Table 3 Global Lymphedema Treatment Market Value, By End Users, 2023, 2027 & 2031 (US$ Billion)

Table 4 Global Lymphedema Treatment Market Value, By Region, 2023, 2027 & 2031 (US$ Billion)

Table 5 Global Lymphedema Treatment Market Value, By Type, 2023, 2027 & 2031 (US$ Billion)

Table 6 Global Lymphedema Treatment Market Value, By Type, 2022-2031 (US$ Billion)

Table 7 Global Lymphedema Treatment Market Value, By Treatment, 2023, 2027 & 2031 (US$ Billion)

Table 8 Global Lymphedema Treatment Market Value, By Treatment, 2022-2031 (US$ Billion)

Table 9 Global Lymphedema Treatment Market Value, By End Users, 2023, 2027 & 2031 (US$ Billion)

Table 10 Global Lymphedema Treatment Market Value, By End Users, 2022-2031 (US$ Billion)

Table 11 Global Lymphedema Treatment Market Value, By Region, 2023, 2027 & 2031 (US$ Billion)

Table 12 Global Lymphedema Treatment Market Value, By Region, 2022-2031 (US$ Billion)

Table 13 North America Lymphedema Treatment Market Value, By Type, 2022-2031 (US$ Billion)

Table 14 North America Lymphedema Treatment Market Value, By Treatment, 2022-2031 (US$ Billion)

Table 15 North America Lymphedema Treatment Market Value, By End Users, 2022-2031 (US$ Billion)

Table 16 North America Lymphedema Treatment Market Value, By Country, 2022-2031 (US$ Billion)

Table 17 South America Lymphedema Treatment Market Value, By Type, 2022-2031 (US$ Billion)

Table 18 South America Lymphedema Treatment Market Value, By Treatment, 2022-2031 (US$ Billion)

Table 19 South America Lymphedema Treatment Market Value, By End Users, 2022-2031 (US$ Billion)

Table 20 South America Lymphedema Treatment Market Value, By Country, 2022-2031 (US$ Billion)

Table 21 Europe Lymphedema Treatment Market Value, By Type, 2022-2031 (US$ Billion)

Table 22 Europe Lymphedema Treatment Market Value, By Treatment, 2022-2031 (US$ Billion)

Table 23 Europe Lymphedema Treatment Market Value, By End Users, 2022-2031 (US$ Billion)

Table 24 Europe Lymphedema Treatment Market Value, By Country, 2022-2031 (US$ Billion)

Table 25 Asia-Pacific Lymphedema Treatment Market Value, By Type, 2022-2031 (US$ Billion)

Table 26 Asia-Pacific Lymphedema Treatment Market Value, By Treatment, 2022-2031 (US$ Billion)

Table 27 Asia-Pacific Lymphedema Treatment Market Value, By End Users, 2022-2031 (US$ Billion)

Table 28 Asia-Pacific Lymphedema Treatment Market Value, By Country, 2022-2031 (US$ Billion)

Table 29 Middle East & Africa Lymphedema Treatment Market Value, By Type, 2022-2031 (US$ Billion)

Table 30 Middle East & Africa Lymphedema Treatment Market Value, By Treatment, 2022-2031 (US$ Billion)

Table 31 Middle East & Africa Lymphedema Treatment Market Value, By End Users, 2022-2031 (US$ Billion)

Table 32 Kite Pharma: Overview

Table 33 Kite Pharma: Product Portfolio

Table 34 Kite Pharma: Key Developments

Table 35 Johnson and Johnson: Overview

Table 36 Johnson and Johnson: Product Portfolio

Table 37 Johnson and Johnson: Key Developments

Table 38 Sanofi S.A: Overview

Table 39 Sanofi S.A: Product Portfolio

Table 40 Sanofi S.A: Key Developments

Table 41 LGM Pharma: Overview

Table 42 LGM Pharma: Product Portfolio

Table 43 LGM Pharma: Key Developments

Table 44 Hubei Xunda Pharma: Overview

Table 45 Hubei Xunda Pharma: Product Portfolio

Table 46 Hubei Xunda Pharma: Key Developments

Table 47 Sigma Aldrich: Overview

Table 48 Sigma Aldrich: Product Portfolio

Table 49 Sigma Aldrich: Key Developments

Table 50 Midas Pharma: Overview

Table 51 Midas Pharma: Product Portfolio

Table 52 Midas Pharma: Key Developments

Table 53 Oishi Koseido Co. Ltd: Overview

Table 54 Oishi Koseido Co. Ltd: Product Portfolio

Table 55 Oishi Koseido Co. Ltd: Key Developments

Table 56 Glentham Life Sciences: Overview

Table 57 Glentham Life Sciences: Product Portfolio

Table 58 Glentham Life Sciences: Key Developments

Table 59 Taro Pharmaceuticals: Overview

Table 60 Taro Pharmaceuticals: Product Portfolio

Table 61 Taro Pharmaceuticals: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Lymphedema Treatment Market Value, 2022-2031 (US$ Billion)

Figure 2 Global Lymphedema Treatment Market Share, By Type, 2023 & 2031(%)

Figure 3 Global Lymphedema Treatment Market Share, By Treatment, 2023 & 2031(%)

Figure 4 Global Lymphedema Treatment Market Share, By End Users, 2023 & 2031(%)

Figure 5 Global Lymphedema Treatment Market Share, By Region, 2023 & 2031(%)

Figure 6 Global Lymphedema Treatment Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 7 Primary Lymphedema Treatment Market Value, 2022-2031 (US$ Billion)

Figure 8 Secondary Lymphedema Treatment Market Value, 2022-2031 (US$ Billion)

Figure 9 Global Lymphedema Treatment Market Y-o-Y Growth, By Treatment, 2022-2030 (%)

Figure 10 Stem Cell Therapy Treatment in Global Lymphedema Treatment Market Value, 2022-2031 (US$ Billion)

Figure 11 Decongestive Therapy Treatment in Global Lymphedema Treatment Market Value, 2022-2031 (US$ Billion)

Figure 12 Surgery Treatment in Global Lymphedema Treatment Market Value, 2022-2031 (US$ Billion)

Figure 13 Drug Therapy Treatment in Global Lymphedema Treatment Market Value, 2022-2031 (US$ Billion)

Figure 14 Laser Therapy Treatment in Global Lymphedema Treatment Market Value, 2022-2031 (US$ Billion)

Figure 15 Others Treatment in Global Lymphedema Treatment Market Value, 2022-2031 (US$ Billion)

Figure 16 Global Lymphedema Treatment Market Y-o-Y Growth, By End Users, 2022-2030 (%)

Figure 17 Hospital End Users in Global Lymphedema Treatment Market Value, 2022-2031 (US$ Billion)

Figure 18 Clinics End Users in Global Lymphedema Treatment Market Value, 2022-2031 (US$ Billion)

Figure 19 Ambulatory Surgical Centers End Users in Global Lymphedema Treatment Market Value, 2022-2031 (US$ Billion)

Figure 20  End Users in Global Lymphedema Treatment Market Value, 2022-2031 (US$ Billion)

Figure 21 Global Lymphedema Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 22 North America Lymphedema Treatment Market Value, 2022-2031 (US$ Billion)

Figure 23 Asia-Pacific Lymphedema Treatment Market Value, 2022-2031 (US$ Billion)

Figure 24 Europe Lymphedema Treatment Market Value, 2022-2031 (US$ Billion)

Figure 25 South America Lymphedema Treatment Market Value, 2022-2031 (US$ Billion)

Figure 26 Middle East and Africa Lymphedema Treatment Market Value, 2022-2031 (US$ Billion)

Figure 27 North America Lymphedema Treatment Market Value, 2022-2031 (US$ Billion)

Figure 28 North America Lymphedema Treatment Market Share, By Type, 2023 & 2031(%)

Figure 29 North America Lymphedema Treatment Market Share, By Treatment, 2023 & 2031(%)

Figure 30 North America Lymphedema Treatment Market Share, By End Users, 2023 & 2031(%)

Figure 31 North America Lymphedema Treatment Market Share, By Country, 2023 & 2031(%)

Figure 32 South America Lymphedema Treatment Market Value, 2022-2031 (US$ Billion)

Figure 33 South America Lymphedema Treatment Market Share, By Type, 2023 & 2031(%)

Figure 34 South America Lymphedema Treatment Market Share, By Treatment, 2023 & 2031(%)

Figure 35 South America Lymphedema Treatment Market Share, By End Users, 2023 & 2031(%)

Figure 36 South America Lymphedema Treatment Market Share, By Country, 2023 & 2031(%)

Figure 37 Europe Lymphedema Treatment Market Value, 2022-2031 (US$ Billion)

Figure 38 Europe Lymphedema Treatment Market Share, By Type, 2023 & 2031(%)

Figure 39 Europe Lymphedema Treatment Market Share, By Treatment, 2023 & 2031(%)

Figure 40 Europe Lymphedema Treatment Market Share, By End Users, 2023 & 2031(%)

Figure 41 Europe Lymphedema Treatment Market Share, By Country, 2023 & 2031(%)

Figure 42 Asia-Pacific Lymphedema Treatment Market Value, 2022-2031 (US$ Billion)

Figure 43 Asia-Pacific Lymphedema Treatment Market Share, By Type, 2023 & 2031(%)

Figure 44 Asia-Pacific Lymphedema Treatment Market Share, By Treatment, 2023 & 2031(%)

Figure 45 Asia-Pacific Lymphedema Treatment Market Share, By End Users, 2023 & 2031(%)

Figure 46 Asia-Pacific Lymphedema Treatment Market Share, By Country, 2023 & 2031(%)

Figure 47 Middle East & Africa Lymphedema Treatment Market Value, 2022-2031 (US$ Billion)

Figure 48 Middle East & Africa Lymphedema Treatment Market Share, By Type, 2023 & 2031(%)

Figure 49 Middle East & Africa Lymphedema Treatment Market Share, By Treatment, 2023 & 2031(%)

Figure 50 Middle East & Africa Lymphedema Treatment Market Share, By End Users, 2023 & 2031(%)

Figure 51 Kite Pharma: Financials

Figure 52 Johnson and Johnson: Financials

Figure 53 Sanofi S.A: Financials

Figure 54 LGM Pharma: Financials

Figure 55 Hubei Xunda Pharma: Financials

Figure 56 Sigma Aldrich: Financials

Figure 57 Midas Pharma: Financials

Figure 58 Oishi Koseido Co. Ltd: Financials

Figure 59 Glentham Life Sciences: Financials

Figure 60 Taro Pharmaceuticals: Financials